MRI诊断脾错构瘤一例

2018-04-04 王传彬 方梦诗 韦超 功能与分子医学影像学杂志(电子版)

患者女,47岁,左侧腰部酸痛不适3个月以上。

【一般资料】

患者女,47岁

【主诉】

左侧腰部酸痛不适3个月以上。

【既往史】

既往体健,无明显不适。

【辅助检查】

轻度贫血,红细胞轻度减少,血小板明显减少,肿瘤指标及生化检查无异常。MRI平扫+多期增强示:脾脏体积增大,实质内见一类圆形肿块影,大小约7.2cm×8.4cm,T1WI、T2WI、DWI序列均呈等信号为主,边界清楚,信号不均,内可见多发长T1长T2信号“血窦样”结构影,周边见弧形受压的流空血管影,增强后动脉期病灶明显不均匀强化,门脉期持续强化并趋向均匀,延迟期与背景脾脏信号相等,未见明显包膜和假包膜结构(图1a~g)。手术所见:肿块切面呈灰红色,镜下瘤体由排列紊乱的裂隙状的血窦样腔隙和内含红细胞的小血管组成,以红髓为主,基质内分布数量不等的淋巴细胞和浆细胞及纤维组织(图1h~i)。病理诊断:脾脏错构瘤(splenichamartoma,SH)。



【讨论】

SH是一种罕见的良性血管性肿瘤样病变,又被称为脾髓增殖性脾大、脾脏的结节样增生等,其发病率约0.024%~0.13%。其病因为脾脏胚基早期发育异常,脾脏正常结构成分组合比例混乱。有报道SH可合并其他部位的错构瘤,但与其他部位错构瘤不同,SH病灶内多无脂肪成分。SH好发于成人,无明显性别差异,多数无症状,临床表现为良性经过,少数可出现血小板减少和贫血,目前尚无特异性的肿瘤标记物。大体标本为境界清楚、无包膜的结节或肿块,膨胀性生长,镜下由排列杂乱的正常脾组织构成,组织形态学表现为无规则的血窦样、管腔状结构,并有紊乱的红髓样间质穿插其中,偶见髓外造血灶,脾索、脾窦结构存在;少数病例可见异型间质细胞,无肿瘤血管生长。免疫组化特征性的表现为管腔衬覆内皮细胞CD8(+),内皮细胞CD31、FⅧ、Vimentin(+)。根据其组成成分不同,分为:①红髓型:主要由失调的脾窦构成;②白髓型:主要由淋巴组织构成;③混合型:红、白髓成分比例较为接近;④纤维型:病灶内部出现纤维化;其中红髓型占大多数,混合型次之。CT平扫表现为脾内等或稍低密度实性肿块,部分病例需根据脾脏轮廓的改变判断肿块是否存在。T1WI序列不同组织类型的肿瘤信号相仿,呈等或稍低信号,边界显示不清;T2WI序列红髓型、白髓型及混合型多呈等或稍高信号,均匀或不均匀,纤维型以低信号为主,信号的高低主要与病灶内红髓脾窦是否扩张以及纤维组织、含铁血黄素所占比例有关;DWI序列病灶信号与T2WI序列相仿,呈等或稍低信号。增强后SH的强化方式由于组织类型和病理基础的不同可以有多种形式,其常见强化模式有两种:①动脉期呈弥漫不均匀轻度强化,门脉期及延迟期呈渐进性强化,对应病理特点为病灶内红髓脾窦无扩张,混杂有部分白髓成分及不同程度的纤维组织增生;②动脉期明显均匀或不均匀强化,门脉期及延迟期持续强化,对应病理特点为病灶内红髓脾窦扩张,血供丰富。两种强化模式的共同特点是早期弥漫性强化,门脉期渐近性或持续性强化,延迟期病灶密度/信号趋向均匀,并接近或稍高于背景脾。本例SH各个序列信号均与脾脏实质相仿,增强后呈第2种强化模式,表明病灶成分与正常脾脏实质成分相近,是一例能够反映其病理组成的典型病例。不常见表现:部分病例以出血、血栓形成为主,延迟期密度/信号不会趋向均匀;纤维型SH内含有纤维组织,可以不强化,或延迟期强化更为明显,密度/信号高于背景脾脏;肿块较大时偶尔可出现“假包膜”;尽管极少数SH可伴有钙化和(或)脂肪组织,但一般认为当脾脏肿块出现钙化和(或)脂肪组织,T2WI序列表现为低信号,应首先考虑SH的诊断。SH主要应与以下病变鉴别:①海绵状血管瘤:T2WI呈高信号(灯泡征),典型的“向心性填充”;②淋巴管瘤:囊性病灶,与SH是实性不同;③淋巴瘤:延迟期密度/信号低于脾实质;④转移瘤:有原发病史,且多发、多部位,鉴别不难;⑤血管肉瘤:侵袭性更明显,DWI序列呈高信号;⑥窦岸细胞血管瘤:常多发,T2WI序列及DWI序列呈高信号,增强后呈“向心性填充”特点。

原始出处:

王传彬,方梦诗,韦超, 等.MRI诊断脾错构瘤一例[J].功能与分子医学影像学杂志(电子版),2017,(4):1331-1333.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=309161, encodeId=0860309161ee, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Apr 25 12:18:59 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492732, encodeId=60811492e3266, content=<a href='/topic/show?id=8df596e229c' target=_blank style='color:#2F92EE;'>#错构瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96722, encryptionId=8df596e229c, topicName=错构瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Apr 06 10:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303138, encodeId=7fe230313886, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 06 02:10:06 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302755, encodeId=ab76302e554c, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 04 20:28:12 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-25 清风拂面

    谢谢分享学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=309161, encodeId=0860309161ee, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Apr 25 12:18:59 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492732, encodeId=60811492e3266, content=<a href='/topic/show?id=8df596e229c' target=_blank style='color:#2F92EE;'>#错构瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96722, encryptionId=8df596e229c, topicName=错构瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Apr 06 10:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303138, encodeId=7fe230313886, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 06 02:10:06 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302755, encodeId=ab76302e554c, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 04 20:28:12 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=309161, encodeId=0860309161ee, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Apr 25 12:18:59 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492732, encodeId=60811492e3266, content=<a href='/topic/show?id=8df596e229c' target=_blank style='color:#2F92EE;'>#错构瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96722, encryptionId=8df596e229c, topicName=错构瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Apr 06 10:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303138, encodeId=7fe230313886, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 06 02:10:06 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302755, encodeId=ab76302e554c, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 04 20:28:12 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-06 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=309161, encodeId=0860309161ee, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Apr 25 12:18:59 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492732, encodeId=60811492e3266, content=<a href='/topic/show?id=8df596e229c' target=_blank style='color:#2F92EE;'>#错构瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96722, encryptionId=8df596e229c, topicName=错构瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Apr 06 10:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303138, encodeId=7fe230313886, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 06 02:10:06 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302755, encodeId=ab76302e554c, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 04 20:28:12 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 虈亣靌

    好好学习天天向上

    0

相关资讯

PNAS:miR-342-5p/AnkG通路可能是老年性痴呆症新的病理机制

阿尔兹海默症(俗称老年性痴呆症)常常被认为是一种与年龄相关的、发生在老年阶段的疾病。然而,生命科学学院张研课题组通过实验证明在家族型阿尔兹海默症小鼠模型中,神经元发育、蛋白运输、轴突起始节功能等方面在发育的早期就表现出了显著的缺陷。Ankyrin G (AnkG)是一种重要的锚定蛋白,对于轴突起始节处的过滤筛选功能起着至关重要的作用。张研课题组的研究发现,在早期阿尔兹海默症模型小鼠中,mi

BJC:循环中miR-199a-5p帮助预测三阴性乳腺癌

三阴性乳腺癌在全球乳腺癌患病女性中占15~20%,这种乳腺癌亚型具有复发早,复发率高的特点,因此患有三阴性乳腺癌的病人生存几率很低,这也与缺少靶向治疗策略具有很大关系。找到三阴性乳腺癌的生物学标记对于三阴性乳腺癌早期诊断及制定有效的治疗方法具有非常重大的意义,同时也是当务之急。

Oncotarget:小身材的大作用——miR-148/miR-152家族的预后价值

本期为大家介绍一篇基于观察研究的系统回顾来评估miR-148/miR-152家族在癌症患者中预后价值的文章。文章发表在Oncotarget期刊上,题目为Evaluatingthe prognostic value of miR-148/152 family in cancers: based on a systemicreview of observational studies(基于观察研究的系

Nat Commun:miR-200可抑制肿瘤血管生成

来自德克萨斯MD安德森癌症中心的研究人员发现,一个叫做miR-200的microRNAs家族可通过抑制肿瘤编织新的血管支持自身的能力,阻断肿瘤的发展和转移。研究报告发表在9月10日的《自然通讯》(Nature Communications)杂志上。【原文阅读】 研究人员发现,如果肺癌、卵巢癌、肾癌或三阴性乳腺癌患者体内表达高水平的miR-200,这些患者寿命会更长一些。 随后